Piper Warns Of Potential For 'Significant' Guidance Cut From Valeant
October 20, 2016 at 17:00 PM EDT
Piper Jaffray analyst David Amsellem told investors that Valeant Pharmaceuticals is likely to fall short of Wall Street expectations, adding that he would not be surprised to see the company make a "major downward revision" to its 2016 guidance.
